Tebentafusp: T cell redirection for the treatment of metastatic uveal melanoma

Metastatic disease from uveal melanoma occurs in almost 50% of patients suffering from this ocular tumour, with median survival from development of symptoms being around 1 year. In contrast to cutaneous melanoma, kinase inhibitors and immune checkpoint inhibitors are usually ineffective in patients...

詳細記述

書誌詳細
主要な著者: Damato, BE, Dukes, J, Goodall, H, Carvajal, RD
フォーマット: Journal article
出版事項: MDPI 2019

類似資料